Skip to main content
. 2016 May 17;7(22):31602–31622. doi: 10.18632/oncotarget.9395

Figure 2. Involvement of ROCK in disorganized phenotype of malignant T4-2 cells in 3D lrECM.

Figure 2

A. Morphological alternations of T4-2 cells treated with ROCK inhibitor (Y-26732 or Fasudil, 3~100 μM). Scale bars: 20 μm. B. Inhibition of proliferation of T4-2 cells treated with ROCK inhibitor (Y-26732 or Fasudil, 3~100 μM), EGFR inhibitor (AG1478, 0.1 μM), MEK inhibitor (PD98059, 10 μM), Integrinβ1 function blocking antibody (AIIB, 100 μg/mL) or EGFR function blocking antibody (mAB225, 4 μg/mL). Cell viability was assessed by MTT assay. Values represent means ± SE of four experiments. **P < 0.01, ***P < 0.001 in the upper graph compared with vehicle control group (Dunnett). ***P < 0.001 in the lower graph compared with vehicle control group (Student's t). C. Down-regulation of EGFR, Integrinβ1, glucose transporter 3 (GLUT3), lactate dehydrogenase A (LDHA), P-MLC and ROCK1 in T4-2 cells treated with ROCK inhibitor (Y-26732, 3~100 μM). Total cell lysates were analyzed by Western blotting with their specific antibodies.